Immodulon appoints CMO

5 June 2023
immodulon_large

UK clinical-stage cancer drug developer Immodulon has appointed Dr Josefine Roemmler-Zehrer as chief medical officer.

She brings a significant track record of clinical and medical affairs success to Immodulon at a key time as the company prepares to advance IMM-101 into a pivotal trial in pancreatic cancer.

Dr Roemmler-Zehrer has had senior leadership roles at leading pharmaceutical companies including Celgene, Amgen (Nasdaq: AMGN) and Ipsen (Euronext: IPN). She has a proven track record of success in several product development programmes including Celgene’s Abraxane (nab-paclitaxel) in pancreatic cancer and NSCLC and Ipsen’s Cabometyx in renal cell carcinoma and thyroid cancer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology